Philips Enters into Collaboration with Janssen to Develop New Handheld Blood Test to Support Care of Patients with Neuropsychiatric Disorders

PhilipsRoyal Philips (NYSE: PHG, AEX: PHIA) has entered into a multi-year development agreement with Janssen Pharmaceutica N.V. (Janssen). The collaboration aims to develop a new handheld blood test to provide doctors with a novel tool to improve the care of patients with neuropsychiatric disorders.

The collaboration unites Philips' expertise in point-of-care testing and monitoring applications for the hospital and the home, with Janssen's strength in discovering and developing innovative solutions to treat brain disorders. Philips will be responsible for the development and manufacturing of the handheld test. The test will be based on Philips' Minicare system, which is currently under development. Janssen will be responsible for the clinical studies to validate the test, as well as the commercialization of the final product.

"Our technology can play an important role in the management of chronic diseases in the hospital and the home," said Frans van Houten, CEO Royal Philips. "Better care for patients with neuropsychiatric disorders is a key driver to improve patient outcomes and lower healthcare costs. The collaboration with Janssen is a great example of our open innovation business model, combining their strength in neuroscience with the biosensor technology in our Minicare I-20 platform."

Mr. Van Houten added: "Going forward, I firmly believe that the Minicare system consisting of the analyzer and application-specific cartridges and software, can be tailored to a wide range of other pharmaceuticals."

The blood test will be based on Philips' Minicare I-20 system for immunoassays, which consists of a handheld analyzer, dedicated software and a single use, disposable cartridge containing the application specific test. Based on Philips' proprietary biosensor technology, the Minicare I-20 system is being developed to detect multiple target molecules at low concentrations within the same blood sample and to show the results on the analyzer display within minutes.

The Minicare activities are part of Philips' Handheld Diagnostics business that has its headquarters and manufacturing lines at the High Tech Campus in Eindhoven, the Netherlands. The business will be expanding its production capacity in light of the new partnership.

Related news articles:

About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a diversified health and well-being company, focused on improving people's lives through meaningful innovation in the areas of Healthcare, Consumer Lifestyle and Lighting. Headquartered in the Netherlands, Philips posted 2014 sales of EUR 21.4 billion and employs approximately 105,000 employees with sales and services in more than 100 countries. The company is a leader in cardiac care, acute care and home healthcare, energy efficient lighting solutions and new lighting applications, as well as male shaving and grooming and oral healthcare.

Most Popular Now

Unlocking the 10 Year Health Plan

The government's plan for the NHS is a huge document. Jane Stephenson, chief executive of SPARK TSL, argues the key to unlocking its digital ambitions is to consider what it...

Alcidion Grows Top Talent in the UK, wit…

Alcidion has today announced the addition of three new appointments to their UK-based team, with one internal promotion and two external recruits. Dr Paul Deffley has been announced as the...

AI can Find Cancer Pathologists Miss

Men assessed as healthy after a pathologist analyses their tissue sample may still have an early form of prostate cancer. Using AI, researchers at Uppsala University have been able to...

AI, Full Automation could Expand Artific…

Automated insulin delivery (AID) systems such as the UVA Health-developed artificial pancreas could help more type 1 diabetes patients if the devices become fully automated, according to a new review...

How AI could Speed the Development of RN…

Using artificial intelligence (AI), MIT researchers have come up with a new way to design nanoparticles that can more efficiently deliver RNA vaccines and other types of RNA therapies. After training...

MIT Researchers Use Generative AI to Des…

With help from artificial intelligence, MIT researchers have designed novel antibiotics that can combat two hard-to-treat infections: drug-resistant Neisseria gonorrhoeae and multi-drug-resistant Staphylococcus aureus (MRSA). Using generative AI algorithms, the research...

AI Hybrid Strategy Improves Mammogram In…

A hybrid reading strategy for screening mammography, developed by Dutch researchers and deployed retrospectively to more than 40,000 exams, reduced radiologist workload by 38% without changing recall or cancer detection...

New Training Year Starts at Siemens Heal…

In September, 197 school graduates will start their vocational training or dual studies in Germany at Siemens Healthineers. 117 apprentices and 80 dual students will begin their careers at Siemens...

Penn Developed AI Tools and Datasets Hel…

Doctors treating kidney disease have long depended on trial-and-error to find the best therapies for individual patients. Now, new artificial intelligence (AI) tools developed by researchers in the Perelman School...

Are You Eligible for a Clinical Trial? C…

A new study in the academic journal Machine Learning: Health discovers that ChatGPT can accelerate patient screening for clinical trials, showing promise in reducing delays and improving trial success rates. Researchers...

New AI Tool Addresses Accuracy and Fairn…

A team of researchers at the Icahn School of Medicine at Mount Sinai has developed a new method to identify and reduce biases in datasets used to train machine-learning algorithms...

Global Study Reveals How Patients View M…

How physicians feel about artificial intelligence (AI) in medicine has been studied many times. But what do patients think? A team led by researchers at the Technical University of Munich...